Lanean...

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review

Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-cell proteins involved in the activation of immune response toward malignancies. Their introduction into clinical practice was a milestone in modern cancer treatment. However, the significant advantage of ICIs...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Endocr Connect
Egile Nagusiak: Stelmachowska-Banaś, Maria, Czajka-Oraniec, Izabella
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Bioscientifica Ltd 2020
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7576644/
https://ncbi.nlm.nih.gov/pubmed/33064663
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EC-20-0342
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!